Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2015, Article ID 197893, 4 pages
http://dx.doi.org/10.1155/2015/197893
Research Article

Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis

1Neurology Department, Los Angeles Biomedical Research Institute, 1124 West Carson Street, Building E5, Torrance, CA 90502, USA
2Department of Neurology, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509, USA

Received 17 April 2015; Accepted 2 June 2015

Academic Editor: Corrado Betterle

Copyright © 2015 Fawzi Abukhalil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. L. Nastuk, O. J. Plescia, and K. E. Osserman, “Changes in serum complement activity in patients with myasthenia gravis,” Proceedings of the Society for Experimental Biology and Medicine, vol. 105, pp. 177–184, 1960. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Padua, E. Stalberg, M. Lomonaco, A. Evoli, A. Batocchi, and P. Tonali, “SFEMG in ocular myasthenia gravis diagnosis,” Clinical Neurophysiology, vol. 111, no. 7, pp. 1203–1207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Keesey, “Clinical evaluation and management of myasthenia gravis,” Muscle and Nerve, vol. 29, no. 4, pp. 484–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Grob, N. Brunner, T. Namba, and M. Pagala, “Lifetime course of myasthenia gravis,” Muscle and Nerve, vol. 37, no. 2, pp. 141–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Deymeer, O. Gungor-Tuncer, V. Ylmaz et al., “Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis,” Neurology, vol. 68, no. 8, pp. 609–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Romi, J. A. Aarli, and N. E. Gilhus, “Seronegative myasthenia gravis: disease severity and prognosis,” European Journal of Neurology, vol. 12, no. 6, pp. 413–418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. J. Oh, M. B. Morgan, L. Lu et al., “Racial differences in myasthenia gravis in Alabama,” Muscle & Nerve, vol. 39, no. 3, pp. 328–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. H. Phillips, “The epidemiology of myasthenia gravis,” Seminars in Neurology, vol. 24, no. 1, pp. 17–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Keesey, “A history of treatments for myasthenia gravis,” Seminars in Neurology, vol. 24, no. 1, pp. 5–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. J. Oh, D. E. Kim, R. Kuruoglu, R. J. Bradley, and D. Dwyer, “Diagnostic sensitivity of the laboratory tests in myasthenia gravis,” Muscle and Nerve, vol. 15, no. 6, pp. 720–724, 1992. View at Publisher · View at Google Scholar · View at Scopus